Leishmania major: Protective capacity of DNA vaccine using amastin fused to HSV-1 VP22 and EGFP in BALB/c mice model

Experimental Parasitology

Volumn 128, Issue 1, 2011, Pages 9-17

  Bolhassani, Azam ^a   Gholami, Elham ^a   Zahedifard, Farnaz ^a   Moradin, Neda ^a   Parsi, Parto ^a,b   Doustdari, Fatemeh ^a   Seyed, Negar ^a   Papadopoulou, Barbara ^c   Rafati, Sima ^a  

^a PASTEUR INSTITUTE OF IRAN   (Iran)

^b Khatam University   (Iran)

^c LAVAL UNIVERSITY   (Canada)

Author keywords

Amastin; Cutaneous leishmaniasis; DNA vaccination; Green fluorescent protein (GFP); Herpes simplex virus type1 VP22 (HSV 1 VP22); Leishmania

Indexed keywords

AMASTIN ENHANCED GREEN FLUORESCENT PROTEIN VP22 FUSION PROTEIN; DNA VACCINE; GAMMA INTERFERON; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G2A ANTIBODY; LEISHMANIA VACCINE; MESSENGER RNA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ARTICLE; CELL STIMULATION; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CYTOKINE RESPONSE; DNA IMMUNIZATION; DRUG ANTIGENICITY; DRUG EFFICACY; DRUG POTENCY; FEMALE; GENE EXPRESSION PROFILING; GENE FUSION; HERPES SIMPLEX VIRUS 1; IMMUNOGENICITY; INFECTION PREVENTION; INTERFERON PRODUCTION; LEISHMANIA MAJOR; LEISHMANIASIS; MONOTHERAPY; MOUSE; NONHUMAN; PARASITE LOAD; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANIMALS; CERCOPITHECUS AETHIOPS; COS CELLS; DISEASE MODELS, ANIMAL; FEMALE; GENE EXPRESSION; GREEN FLUORESCENT PROTEINS; INTERFERON-GAMMA; INTERLEUKIN-5; LEISHMANIA MAJOR; LEISHMANIASIS, CUTANEOUS; MEMBRANE GLYCOPROTEINS; MEMBRANE PROTEINS; MICE; MICE, INBRED BALB C; PROTOZOAN PROTEINS; PROTOZOAN VACCINES; RECOMBINANT FUSION PROTEINS; TRANSFECTION; VACCINES, DNA; VIRAL STRUCTURAL PROTEINS;

HUMAN HERPESVIRUS 1; LEISHMANIA MAJOR; MUS; SIMPLEXVIRUS;

EID: 79952902145     PISSN: 00144894     EISSN: 10902449     Source Type: Journal    
DOI: 10.1016/j.exppara.2011.01.012     Document Type: Article

References (39)

1. Aghaei N., Zahedifard F., Weiss R., Sarbolouki M.N., Thalhamer J., Rafati S. Protective efficiency of dendrosomes as novel nano-sized adjuvants for DNA vaccination against birch pollen allergy. Journal of Biotechnology 2006, 124:602-614.
2. Bolhassani A., Zahedifard F., Taghikhani M., Rafati S. Enhanced immunogenicity of HPV16E7 accompanied by Gp96 as an adjuvant in two vaccination strategies. Vaccine 2008, 26:3362-3370.
3. Bolhassani A., Ghasemi N., Servis C., Taghikhani M., Rafati S. The efficiency of a novel delivery system (PEI600-Tat) in development of potent DNA vaccine using HPV16 E7 as a model antigen. Drug Delivery 2009, 16:196-204.
4. Bolhassani A., Taghikhani M., Ghasemi N., Soleimanjahi H., Rafati S. Comparison of two delivery systems efficiency by using polyethylenimine (PEI) for plasmid HPV16E7 DNA transfection into COS-7 cells. Modarres Journal of Medical Sciences 2008, 11:15-19.
5. Buffet P.A., Sulahian A., Garin Y.J.F., Nassar N., Derouin F. Culture microtitration: a sensitive method for quantifying Leishmania infantum in tissues of infected mice. Antimicrobial Agents and Chemotherapy 1995, 2167:8.
6. Doria-Rose N.A., Haigwood N.L. DNA vaccine strategies: candidates for immune modulation and immunization regimens. Methods 2003, 31:207-216.
7. Dunning N. Leishmania vaccines: from leishmanization to the era of DNA technology. Bioscience Horizons 2009, 2:73-82.
8. Elliott G., O'Hare P. Intercellular trafficking and protein delivery by a herpesvirus structural protein. Cell 1997, 88:223-233.
9. Gambotto A., Dworacki G., Cicinnati V., Kenniston T., Steitz J., Tuting T., Robbins P.D., Deleo A.B. Immunogenicity of enhanced green fluorescent protein (EGFP) in BALB/c mice. identification of an H2-Kd-restricted CTL epitope. Gene Therapy 2000, 7:2036-2040.
10. Hellgren I., Gorman J., Sylven C. Factors controlling the efficiency of Tat-mediated plasmid DNA transfer. Journal of Drug Targeting 2004, 12:39-47.
11. Hung C.F., He L., Juang J., Lin T.J., Ling M., Wu T.C. Improving DNA vaccine potency by linking Marek's disease virus type 1 VP22 to an antigen. Journal of Virology 2002, 76:2676-2682.
12. Ivens A.C., Peacock C.S., Worthey E.A., Murphy L., Aggarwal G., Berriman M., Sisk E. The genome of the kinetoplastid parasite Leishmania major. Science 2005, 309:342-346.
13. Javer P., Langel U. The use of cell-penetrating peptides as a tool for regulation. Drug Discovery Today 2004, 9:395-402.
14. Khoshgoo N., Zahedifard F., Azizi H., Taslimi Y., Alonso M.J., Rafati S. Cysteine proteinase type III is protective against Leishmania infantum infection in BALB/c mice and highly antigenic in visceral leishmaniasis individuals. Vaccine 2008, 26:5822-5829.
15. Liu L., Zhou X., Liu H., Xiang L., Yuan Z. CpG motif acts as a "danger signal" and provides a T helper type 1-biased microenvironment for DNA vaccination. Immunology 2005, 115:223-230.
16. Mendez S., Belkaid Y., Seder R.A., Sacks D. Optimization of DNA vaccination against cutaneous leishmaniasis. Vaccine 2002, 20:3702-3708.
17. Michel N., Osen W., Gissmann L., Schumacher N.M., Zentgraf H., Muller M. Enhanced immunogenicity of HPV16E7 fusion proteins in DNA vaccination. Virology 2002, 294:47-59.
18. Oliveira S.C., Harms J.S., Afonso R.R., Splitter G.A. A genetic immunization adjuvant system based on BVP22-antigen fusion. Human gene therapy 2001, 12:1353-1359.
19. Ortiz M.L., Calero M., Fernandez Patronc C., Patron C.F., Castellanos L., Mendez E. Imidazole-SDS-Zn reverse staining of proteins in gels containing or not SDS and micro-22 sequence of individual unmodified electro-blotted proteins. European Journal of Biochemistry 1992, 296:300-304.
20. Palatnik-de-Sousa C.B. Vaccines for leishmaniasis in the fore coming 25 years. Vaccine 2008, 26:1709-1724.
21. Perkins S.D., Hartley M.G., Lukaszewski R.A., Phillpotts R.J., Stevenson F.K., Bennett A.M. VP22 enhances antibody responses from DNA vaccines but not by intercellular spread. Vaccine 2005, 23:1931-1940.
22. Rafati S., Hassani N., Taslimi Y., Movassagh H., Rochette A., Papadopoulou B. Amastin peptide binding antibodies as biomarkers of active human visceral leishmaniasis. Clinical and Vaccine Immunology 2006, 13:1104-1110.
23. Rafati S., Salmanian A.H., Taheri T., Vafa M., Fasel N. A protective cocktail vaccine against murine cutaneous leishmaniasis with DNA encoding cysteine proteinases of Leishmania major. Vaccine 2001, 19:3369-3375.
24. Rafati S., Ghaemimanesh F., Zahedifard F. Comparison of potential protection induced by three vaccination strategies (DNA/DNA, protein/protein and DNA/protein) against Leishmania major infection using signal peptidase type I in BALB/c mice. Vaccine 2006, 24:3290-3297.
25. Re F., Srinivasan R., Igarashi T., Marincola F., Childs R. Green fluorescent protein expression in dendritic cells enhances their immunogenicity and elicits specific cytotoxic T cell responses in humans. Experimental Hematology 2004, 32:210-217.
26. Reithinger R., Dujardin J., Louzir H., Reithinger R., Dujardin J.C., Louzir H., Pirmez C., Alexander B., Brooker S. Cutaneous leishmaniasis. The Lancet Infectious Diseases 2007, 7:581-596.
27. Rochette A., Raymond F., Ubeda J.M., Smith M., Messier N., Boisvert S., Rigault P., Corbeil J., Ouellette M., Papadopoulou B. Genome-wide gene expression profiling analysis of Leishmania major and Leishmania infantum developmental stages reveals substantial differences between the two species. BMC Genomics 2008, 29:255-281.
28. Rochette A., McNicoll F., Girard J., Breton M., Leblanc E., Bergeron M.G., Papadopoulou B. Characterization and developmental gene regulation of a large gene family encoding amastin surface proteins in Leishmania spp. Molecular and Biochemical Parasitology 2005, 140:205-220.
29. Rodriguez-Cortes A., Ojeda A., Lopez-Fuertez L., Altet L., Solano-Gallego L., Snchez-Robert E., Francino O., Alberola J. Vaccination with plasmid DNA encoding KMPII, TRYP, LACK and GP63 does not protect dogs against Leishmania infantum experimental challenge. Vaccine 2007, 25:7962-7971.
30. Rosenzweig M., Connole M., Glickman R., Yue S.P., Noren B., DeMaria M., Johnson R.P. Induction of cytotoxic T lymphocyte and antibody responses to enhanced green fluorescent protein following transplantation of transduced CD34 (+) hematopoietic cells. Blood 2001, 97:1951-1959.
31. Salotra P., Duncan R.C., Singh R., Subba Raju B.V., Sreenivas G., Nakhasi H.L. Up-regulation of surface proteins in Leishmania donovani isolated from patients of post kala-azar dermal leishmaniasis. Microbes and Infection 2006, 8:637-644.
32. Sharma U., Singh S. Immunobiology of leishmaniasis. Indian Journal of Experimental Biology 2009, 47:412-423.
33. Skelton D., Satake N., Kohn D.B. The enhanced green fluorescent protein (EGFP) is minimally immunogenic in C57BL/6 mice. Gene Therapy 2001, 8:1813-1815.
34. Stober C.B., Lange U.G., Roberts M.T.M., Gilmartin B., Francis R., Almeida R. From genome to vaccines for leishmaniasis: screening 100 novel vaccine candidates against murine Leishmania major infection. Vaccine 2006, 24:2602-2616.
35. Tian C., Bagley J., Kaye J., Iacomini J. Induction of T cell tolerance to a protein expressed in the cytoplasm through retroviral-mediated gene transfer. The Journal of Gene Medicine 2003, 5:359-365.
36. Viana da costa A., Huerre M., Delacre M., Auriault C., Correia costa J.M., Verwaerde C. IL-10 leads to a higher parasite persistent mouse model of Leishmania major infection. Parasitology International 2002, 51:367-379.
37. Wagstaff K.M., Jans D.A. Protein transduction: cell penetrating peptides and their therapeutic applications. Current Medicinal Chemistry 2006, 13:1371-1387.
38. Wu Y., Youssef E., Fakhry L., Sereno D., Samira T., Papadopoulou B. A new developmentally regulated gene family in Leishmania amastigotes encoding a homolog of amastin surface proteins. Molecular and Biochemical Parasitology 2000, 110:345-357.
39. Zheng C.F., Brownlie R., Huang D.Y., Babiuk L.A., Hurk S.D.L. Intercellular trafficking of the major tegument protein VP22 of bovine herpesvirus-1 and its application to improve a DNA vaccine. Archives of Virology 2006, 151:985-993.